Zymeworks Licenses Drug to Roche in $813M Deal
Zymeworks has agreed to license its experimental lung cancer drug ZW209 to Roche in a deal worth up to $813 million. The agreement includes an upfront payment of $55 million and potential milestone payments.
Xurve View
Insights:
Xurve View
ZYMEWORKS INC licensed its experimental lung cancer drug ZW209 to ROCHE HOLDING AG-BR in a deal worth up to $813M on Friday afternoon. The agreement expands Switzerland-based Roche's oncology pipeline into trispecific T-cell engagers. The partnership provides Zymeworks with upfront capital and milestones to advance clinical development.
